《益生菌混合物VSL#3：慢性疾病基础与临床研究综述》勘误
Corrigendum to "Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases".
作者信息
Sang Li-Xuan
机构信息
Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China.
出版信息
World J Clin Cases. 2021 Jul 16;9(20):5752-5753. doi: 10.12998/wjcc.v9.i20.5752.
Abstract
[This corrects the article on p. 1361 in vol. 8, PMID: 32368530.].
摘要
[这更正了第8卷第1361页的文章，PMID: 32368530。]
相似文献
1
Corrigendum to "Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases".《益生菌混合物VSL#3：慢性疾病基础与临床研究综述》勘误
World J Clin Cases. 2021 Jul 16;9(20):5752-5753. doi: 10.12998/wjcc.v9.i20.5752.
2
Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases.益生菌合剂VSL#3：慢性病基础与临床研究综述
World J Clin Cases. 2020 Apr 26;8(8):1361-1384. doi: 10.12998/wjcc.v8.i8.1361.
3
Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice.益生菌混合物VSL#3可减轻Muc2粘蛋白缺陷小鼠的结肠炎症并改善肠道屏障功能。
Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G34-G45. doi: 10.1152/ajpgi.00298.2016. Epub 2016 Nov 17.
4
Corrigendum.勘误
Paediatr Child Health. 2015 Nov-Dec;20(8):466-7. doi: 10.1093/pch/20.8.466.
5
Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity.一种多菌种益生菌制剂的代谢变异性对抗炎活性产生影响。
Front Pharmacol. 2017 Jul 28;8:505. doi: 10.3389/fphar.2017.00505. eCollection 2017.
6
Evaluation of the efficacy of probiotic VSL#3 and synbiotic VSL#3 and yacon-based product in reducing oxidative stress and intestinal permeability in mice induced to colorectal carcinogenesis.评价益生菌 VSL#3、合生菌 VSL#3 和以雪莲果为基础的产品在减少诱导结直肠癌变的小鼠氧化应激和肠道通透性方面的功效。
J Food Sci. 2021 Apr;86(4):1448-1462. doi: 10.1111/1750-3841.15690. Epub 2021 Mar 24.
7
VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-γ-induced Intestinal Epithelial Barrier Defects.VSL#3益生菌刺激T细胞蛋白酪氨酸磷酸酶介导的γ-干扰素诱导的肠上皮屏障缺陷的恢复。
Inflamm Bowel Dis. 2016 Dec;22(12):2811-2823. doi: 10.1097/MIB.0000000000000954.
8
Amelioration of intestinal and systemic sequelae of murine infection by probiotic VSL#3 treatment.益生菌VSL#3治疗改善小鼠感染后的肠道及全身后遗症。
Gut Pathog. 2017 Apr 11;9:17. doi: 10.1186/s13099-017-0168-y. eCollection 2017.
9
The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells.VSL#3益生菌配方可诱导结肠上皮细胞中粘蛋白基因的表达和分泌。
Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G315-22. doi: 10.1152/ajpgi.00265.2006. Epub 2006 Sep 14.
10
The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.益生菌组合VSL#3对小鼠进行广谱抗生素治疗后的黏膜、外周和全身免疫具有调节作用。
Front Cell Infect Microbiol. 2017 May 5;7:167. doi: 10.3389/fcimb.2017.00167. eCollection 2017.
引用本文的文献
1
Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.肠道微生物群与宿主相互作用在克罗恩病发病机制中的作用及机制
Int J Colorectal Dis. 2025 May 28;40(1):130. doi: 10.1007/s00384-025-04917-7.
本文引用的文献
1
Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases.益生菌合剂VSL#3：慢性病基础与临床研究综述
World J Clin Cases. 2020 Apr 26;8(8):1361-1384. doi: 10.12998/wjcc.v8.i8.1361.
Zotero 插件